Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 22.7% in February

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 2,490,000 shares, a decrease of 22.7% from the February 13th total of 3,220,000 shares. Based on an average trading volume of 676,300 shares, the days-to-cover ratio is presently 3.7 days. Currently, 2.0% of the shares of the company are sold short.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company's stock, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by company insiders.

Remove Ads

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Capital World Investors boosted its position in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after purchasing an additional 98,303 shares in the last quarter. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ALNY. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 11th. Scotiabank lowered their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday, February 14th. Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, StockNews.com raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $304.26.

Alnylam Pharmaceuticals Trading Up 0.3 %

Shares of ALNY stock traded up $0.79 during trading hours on Thursday, reaching $254.23. The company's stock had a trading volume of 727,867 shares, compared to its average volume of 790,852. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The stock has a market capitalization of $32.91 billion, a P/E ratio of -117.55 and a beta of 0.39. The firm's fifty day simple moving average is $255.99 and its 200 day simple moving average is $259.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.